Bristol’s Opdivo Delay May Help It Beat Out BRAF Inhibitors
This article was originally published in The Pink Sheet Daily
Firm announces three-month user fee extension for first-line melanoma claim for Opdivo, but the firm’s statement suggests a silver lining.
You may also be interested in...
With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?
In Bristol’s CheckMate 067, PD-1 monotherapy performs as well as the PD-1/CTLA-4 combination in melanoma patients with higher expression of the PD-L1 biomarker, a finding that implies a personalized immunotherapy approach in the future.
From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research.